Martin Vazquez - Mar 1, 2023 Form 4 Insider Report for Outset Medical, Inc. (OM)

Role
Chief Operating Officer
Signature
By: John L Brottem For: Martin Vazquez
Stock symbol
OM
Transactions as of
Mar 1, 2023
Transactions value $
-$92,251
Form type
4
Date filed
3/2/2023, 05:18 PM
Previous filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OM Common Stock Options Exercise $19.4K +5K +4.85% $3.88* 108K Mar 1, 2023 Direct
transaction OM Common Stock Sale -$112K -5K -4.62% $22.33 103K Mar 1, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OM Performance Options (right to buy) Options Exercise $0 -5K -10.31% $0.00 43.5K Mar 1, 2023 Common Stock 5K $3.88 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from: $21.00 - $21.99 - 362 shares; $22.00 - $22.99 - 4,637 shares; $23.00 - $23.99 - 1 share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote.
F3 Includes 608 shares of Common Stock acquired pursuant to the Outset Medical, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the purchase period of September 1, 2022 to February 28, 2023. This transaction is exempt from Rule 16b-3(c).
F4 In March 2021, following the expiration of the lock-up period in connection with our initial public offering, the applicable performance and market-based vesting conditions were met and the shares underlying this stock option award became fully vested.